ALZA Corp. is a pharmaceutical and medical systems company that develops, manufactures, and markets therapeutic systems. It provides oral, transdermal, implantable, and liposomal technologies. It is also focused on drug delivery systems with over 20 prescription pharmaceutical products. With over 10,000 employees, ALZA Corp. is a subsidiary of Johnson & Johnson. It was established in 1968 by Dr Alejandro Zaffaroni. It is based inVacaville, California.

Shasun is an integrated, leading global supplier of development and manufacturing services for intermediates, API (Active Pharmaceutical Ingredients) and Formulations to the Pharmaceutical Industry. Our mission is to be the preferred partner and provider of services to our customers. We pride ourselves on our ability to offer flexible, tailored solutions to our clients and our unparalleled expertise and commitment to customer service and quality ensure that all aspects of clients’ projects are executed to the highest level.

Conquer is an enterprise company focusing on high-end chemical drugs for diabetes. The company integrates scientific research, production, and sales, and has gradually developed into a comprehensive innovative enterprise that mainly produces tablets and capsules, and also produces some APIs. Conquer was established in 1999 and is based in Chongqing, China.

AstraZeneca is an innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines that are innovative, effective, and which offer added benefits such as reduced side effects or better ways of taking the treatment. AstraZeneca focuses on getting the best from every medicine they make by exploring all the ways it can be used or improved. AstraZeneca was established on April 6, 1999, in Cambridgeshire, United Kingdom.

Hefei Huafang Pharmaceutical Technology Co., Ltd., established on 2003-12-01, Business scope includes drug research and development,Pharmaceutical new technology,New technology research design and transfer;food,cosmetic,Chemicals,Technical design of chemical products,consult,introduce,analysis test;pharmaceutical production,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Established in 1997, S.L.A. Pharma AG is one of the few pharmaceutical companies in the world focused solely on developing medicines for the prevention and treatment of gastrointestinal disorders. S.L.A. Pharma is a privately owned company, located outside Basel in Switzerland with an operations arm in the UK. Their dedicated team includes experienced pharmaceutical, medical and regulatory professionals with the required knowledge and expertise to drive the product from conception through to launch. Working alongside a global network of top gastroenterologists and colorectal surgeons – offering outstanding combined expertise, S.L.A. Pharma has developed a product pipeline covering familial adenomatous polyposis, anal fissures, perianal Crohn's disease, opioid induced constipation and faecal incontinence.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Sichuan Baili Pharmaceutical Co., Ltd., established on 1996-08-23, Business scope includes licensed projects:pharmaceutical production;Health food production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Import and export;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Cosmetics Wholesale;Healthy food(prepackaged)Sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Manufactures pharmaceuticals

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Anhui Xinxing Drug Development Co., Ltd., established on 1998-04-30, Business scope includes general business items:medicine,pesticide,food formula,chemical industry,Medical equipment research and development,technology transfer,Information Consulting;one,Class II medical device,Chemical products and raw materials(Does not contain dangerous goods)promotion of;Import and export business operation(Exclusions prescribed or prohibited by the state).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Memory Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer's disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company was incorporated in 1997 and is based in Montvale, New Jersey. As of December 31, 2008, Memory Pharmaceuticals Corp. operates as a subsidiary of Hoffmann-La Roche Inc.

Dezhou Deyao Pharmaceutical Co., Ltd., established on 2003-12-29, Business scope includes production and sales:Freeze-dried powder injection(Contains antineoplastic drugs),tablet,hard capsule,Granules,Pills,API(Cisplatin,Azithromycin Fumarate,caffeic acid,Esmolol Hydrochloride,Pemetrexed Disodium,Gemcitabine Hydrochloride).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

The mission of Cavalon Therapeutics, Inc is to develop best in class medicines for neurodegenerative and neuropsychiatric diseases. Cavalon has established proprietary insights and drug development strategies based on an understanding of the role of plasma membrane calcium channels in CNS diseases. Our first therapeutic programs focus on breakthrough medicines for Parkinson’s disease and Opioid Use Disorder (OUD), two large markets with significant unmet needs. Cavalon was founded by an experienced team of entrepreneurs and scientists from industry and academia. The company is built around discoveries made by Dr. James Surmeier, one of the company's co-founders, and Cavalon has access to key technology and intellectual property from Northwestern University. Cavalon Therapeutics is supported by grant funding from the Michael J. Fox Foundation for Parkinson's Research.

Shanghai Yangfan Pharmaceutical Technology Co., Ltd., established on 2004-08-10, Business scope includes pharmaceuticals,Research and development of fine chemicals,Pharmaceutical Intermediates(In addition to drugs)promotion of.And provide related technology development,technology transfer,technical consulting,Technical Services,Import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Jiangsu Beida Pharmaceutical Technology Co., Ltd., established on 2010-12-13, The scope of business includes the operation of hazardous chemicals[According to the certificate number for SU(Sue)Hazardous Scriptures(Wujiang)00076Licensed scope and mode of operation listed in the No.];Research and development of pharmaceutical intermediates,Sales;biology,Technology development in the field of medicine,technology transfer,technical consulting;Chemical raw materials and products(Free of Hazardous Chemicals),Chemical equipment and accessories,laboratory equipment,Non-ferrous metals,metallic material,Metal Products Sales;Computer software and hardware development,Sales;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain. It was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Beijing Shuishengmu Technology Co., Ltd., established on 2005-01-28, Business scope includes technology development,Serve;Organize cultural and artistic exchange activities;translation service;Information Consulting;Sell ​​metal materials;Technology Import and Export.(Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments.)